Home » Stock Quotes » EBR:ACPH

Acacia Pharma Group PLC

EBR:ACPH Share Price & Live Data

2.19 EUR
-0.02 (-0.68%)
Price open 2.12
Previous close 2.20
Market cap 140.10M
Volume 121.87K
Day high 2.25
Day low 2.12
Year high 4.00
Year low 1.29

About Acacia Pharma Group PLC

Acacia Pharma Group plc, a hospital pharmaceutical company, focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients in the United States and internationally. The company's lead product is BAREMSIS, an intravenous formulation of amisulpride that has completed Phase III clinical trials for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also comprise APD403 that has completed Phase II clinical trials for the chemotherapy-induced nausea and vomiting treatment. The company was founded in 2007 and is based in Cambridge, the United Kingdom.

Name Acacia Pharma Group PLC
Exchange Brussels Stock Exchange
Sector Healthcare
Industry Biotechnology
Country United Kingdom
Full time employees 33

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.